StockMarketWire.com - Indivior said Wednesday a US court had denied rival Dr. Reddy's Laboratories request to immediately be granted the right to sell a generic version of the company's opioid addiction treatment.
The ruling ensured the injunction against Dr. Reddy's Laboratories would remain in place until after the mandate issues, Indivior said.
Indivior said it would file a petition by Dec.20, on the previous ruling, which had lifted the injunction, affirming that the court must rule on the petition before the mandate can be issued.
'We are pleased that the Court has denied DRL's motion to immediately issue the mandate,' said Shaun Thaxter, CEO of Indivior. 'We will continue to vigorously pursue our infringement cases against DRL to protect our SUBOXONE (buprenorphine and naloxone) Sublingual Film patent portfolio.'
At 8:17am: [LON:INDV] Indivior Plc share price was +1.61p at 86.41p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.